Literature DB >> 34137365

Serum otolin-1 as a biomarker for benign paroxysmal positional vertigo: a case-control study.

D V K Irugu1, A Singh1, H Yadav1, H Verma1, R Kumar1, R A Abraham2, L Ramakrishnan2.   

Abstract

OBJECTIVES: This study aimed to evaluate serum otolin-1 levels in patients with benign paroxysmal positional vertigo and to compare these levels with healthy individuals.
METHOD: This was a case-control study. After obtaining institutional ethical committee clearance, the serum level of otolin-1 was calculated in adult individuals (18-75 years old) who were divided into group 1 (patients presenting with benign paroxysmal positional vertigo) and group 2 (healthy patients without benign paroxysmal positional vertigo as the control group). Data analysis was carried out to compare the serum levels in the cases and controls. A p-value less than 0.05 was considered significant.
RESULTS: A total of 70 age-matched individuals (cases, n = 40; controls, n = 30) were included in the study. The mean serum level of otolin-1 was 636.8 pg/ml (range, 259-981 pg/ml) in the group of patients with benign paroxysmal positional vertigo and 236.2 pg/ml (range, 189-370 pg/ml) in the control group. The difference was statistically significant (p = 0.0000).
CONCLUSION: The serum levels of otolin-1 in patients with benign paroxysmal positional vertigo are significantly higher compared with individuals without benign paroxysmal positional vertigo.

Entities:  

Keywords:  Benign Paroxysmal Positional Vertigo; Biomarker; Otolithic Membrane; Semicircular Canals

Year:  2021        PMID: 34137365     DOI: 10.1017/S0022215121001274

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  High Serum Levels of Otolin-1 in Patients With Benign Paroxysmal Positional Vertigo Predict Recurrence.

Authors:  Zhenyi Fan; Zhizhou Hu; Weiwei Han; Xiaoxiong Lu; Xiaoxia Liu; Min Zhou; Wang Yan; Yunqin Wu
Journal:  Front Neurol       Date:  2022-03-14       Impact factor: 4.003

2.  Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway.

Authors:  Jing Hui; Qi Lei; Zhi Ji; Dingjing Zi
Journal:  Biol Res       Date:  2022-04-04       Impact factor: 5.612

Review 3.  Advances in otolith-related protein research.

Authors:  Shouju Huang; Shuxia Qian
Journal:  Front Neurosci       Date:  2022-07-26       Impact factor: 5.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.